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Regular performance of medication reviews is prominent among methods thatAbstract
have been advocated to reduce the extent and seriousness of drug-related
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problems, such as adverse drug reactions, drug-disease interactions, drug-drug
interactions, drug ineffectiveness and cost ineffectiveness. Several screening tools
have been developed to guide practising healthcare professionals and researchers
in reviewing the medication patterns of elderly patients; however, each of these
tools has its own limitations. This review discusses a wide range of general
prescription-, treatment- and patient-related issues that should be taken into
account when reviewing medication patterns by implicit screening. These include
generic and therapeutic substitution; potentially superfluous or inappropriate
medications; potentially inappropriate dosages or duration of treatment; drug-
disease and drug-drug interactions; under-treatment; making use of laboratory test
results; patient adherence, experiences and habits; appropriate dosage forms and
packaging. A broad selection of specific examples and references that can be used
as a basis for explicit screening of medication patterns in outpatients is also
offered.
Patients using repeat prescriptions are at risk of paying a fee to community pharmacists for con-
ducting medication reviews of outpatients receivingexperiencing adverse drug reactions, drug-disease
polypharmacy.[12,13]interactions, drug-drug interactions and drug inef-
fectiveness, particularly when they are elderly. This The UK Task Force on Medicines Partnership
is due to factors such as polypharmacy, suboptimal distinguishes four different levels of medication re-
monitoring, non-adherence and pathological or age- views (table I). Pharmacists in the UK are allowed to
claim payment for so-called medicine use reviews,related physiological changes. Regular performance
which aim at improving the patient’s knowledge andof pharmacy-initiated medication reviews is promi-
use of drugs by, in particular: (i) establishing thenent among methods that have been advocated to re-
patient’s actual use, understanding, and experienceduce the extent and seriousness of such
of taking drugs; (ii) identifying, discussing andproblems.[1-3] Drug treatments should be periodical-
resolving poor or ineffective use of drugs by thely reconsidered in terms of their adverse effects.
patient; (iii) identifying adverse effects and drugRandomised controlled trials have partially con-
interactions that may affect the patient’s adherencefirmed that pharmacy-initiated medication reviews
to instructions given to him or her by a healthcaremay have economic as well as clinical benefits, if
professional; and (iv) improving the clinical anddesigned and executed appropriately.[1,2,4-10]
cost effectiveness of drugs prescribed to patients,In several countries, pharmacists can now claim a
thereby reducing the wastage of such drugs.[14]fee for conducting medication reviews of outpa-
tients. Australian community pharmacists are com- 1. Objectivespensated for home medicine reviews under an agree-
ment between the government and the pharmacy The growing importance of medication reviews
guild. In cooperation with a general practitioner increases the need for adequate guidance on how to
(GP) [who refers the patient], the pharmacist visits perform such reviews, particularly in elderly pa-
the patient at home, reviews his or her medications tients with complicated drug regimens. This article
and provides the GP with a report. The GP and examines prominent existing tools for conducting
patient then agree on a medication management reviews and then presents a new composite tool that
plan. The pharmacist’s responsibilities vary, de- provides (i) an approach to various general issues
pending on whether he or she is accredited to con- that should be taken into account in the implicit
duct medication reviews.[11] In The Netherlands, reviewing of medication patterns; and (ii) a broad
private health insurance companies have started range of specific examples and detailed references
© 2007 Adis Data Information BV. All rights reserved. Drugs Aging 2007; 24 (9)
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Table I.  Levels of medication review distinguished by the UK Task Force on Medicines Partnership (reproduced from Shaw et al.,[15] with
permission)
Level Type of review Description
0 Ad hoc review Unstructured, opportunistic review of a patient’s medication
For example, an isolated question to a patient from a receptionist in the surgery or from a pharmacist
in the community pharmacy
1 Prescription review Technical review of a list of a patient’s medicines
This can be helpful in identifying anomalies and highlighting patients who may need clinical medication
reviews, but as a stand-alone tool its benefits are relatively limited as it does not normally allow for a
full discussion with the patient. Examples of interventions include dose and pack optimisation, resolving
quantity problems, drug presentation issues and brand-to-generic switches
2 Treatment review Review of medicines with patient’s full notes
This normally takes place under the direction of a doctor, nurse or pharmacist, but often without the
patient (e.g. removal of unwanted items from the repeat medicines list, dose adjustments). It may
include the complete repeat prescription or focus on one therapeutic area (e.g. hypertension), drug
(e.g. lithium) or group of drugs (e.g. NSAIDs). Recommendations may be passed to the prescriber for
implementation. Examples of outcomes include reducing the number of items and modifying doses
3 Clinical medication Face-to-face review of medicines and condition
review This requires access to the patient’s notes, a full record of prescriptions and non-drug care and results
from laboratory tests. It should include the complete repeat prescription as well as over-the-counter and
complementary remedies. In a clinical medication review, medicines are not examined in isolation but
considered in the context of the patient’s condition and the way he/she lives his/her life. The review
should involve the patient as a full partner (i.e. listening to the patient’s views and beliefs about his/her
medicines, reaching an honest understanding of his/her medicine-taking behaviour and taking full
account of his/her preferences in any decisions about treatment). The invitation to a review should
include both the patient and (when appropriate) the carer. The level 3 clinical medication review
involves evaluating the therapeutic efficacy of each drug, identifying and addressing unmet therapeutic
needs, monitoring the progress of the conditions being treated, and purposefully discussing specific
aspects of the patient’s medication with the aim of facilitating a concordant approach to medicine
taking. A clinical medication review may take place in a variety of settings, including the patient’s home
to examples that can be used for the explicit review- our initial MEDLINE search with an incremental
ing of medication patterns. search strategy that comprised the following ele-
ments:
• Manual searching of the literature that had al-2. Methods
ready been collected or consulted for our earlier
studies.[2,16,17] As these studies had focused onOur initial search strategy for finding pertinent
ambulatory care patients, we decided to give ourarticles was a free text search on ‘medication re-
new study the same focus.view’ OR ‘medication reviews’ in MEDLINE
• Online searching for additional papers by thethrough online consultation of PubMed from 1965
research groups that were found to be prominentto 31 December 2006. We resorted to this free text
in the field of medication reviews and relatedapproach because PubMed did not provide a specific
issues.MeSH term for medication review. Only 141 refer-
• Manual searching of the bibliography of everyences were retrieved, many of which were judged
useful reference retrieved for additional refer-(on the basis of their title and/or abstract) to be not
ences and repeating this procedure until no moreuseful for our purposes. More importantly, the
useful references emerged.search failed to identify various relevant articles that
we had uncovered in the course of an earlier litera-
ture review on repeat prescribing in ambulatory care 3. Existing Screening Tools
patients[2] and two original studies of prescriber- and
user-related problems in elderly outpatients receiv- Several implicit and/or explicit screening tools
ing polypharmacy.[16,17] We therefore supplemented have been developed to guide practising healthcare
© 2007 Adis Data Information BV. All rights reserved. Drugs Aging 2007; 24 (9)
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professionals as well as drug utilisation researchers and consists of a list of specific drugs and drug
in reviewing the medication patterns of elderly pa- classes that should generally be avoided in elderly
tients; however, each of them has its own benefits patients. These so-called Beers criteria have been
and limitations. This is illustrated in this section by very useful for assessing medication appropriate-
discussion of some prominent examples. ness in elderly populations, and they have been
widely used for this purpose.[20-23] When interpret-Generally speaking, implicit screening criteria
ing such data, however, it is important to appreciate(e.g. look for inappropriate drug-drug interactions)
that some drugs on the Beers list are appropriate forallow a full and flexible clinical judgement of indi-
specific patients in certain circumstances.[24,25] Fur-vidual drug treatments in a way that can also detect
thermore, the original Beers criteria focused entirelyproblems that are not pre-specified. However, im-
on the appropriateness of medications in elderlyplicit screening methods depend heavily on the
patients without addressing other important catego-knowledge, experience and skills of the individual
ries of drug-related problems. In 2003, an additionalreviewer. They may be relatively time consuming
Beers list was introduced that specified certain drug-and it can be difficult to apply them consistently and
disease combinations that should also generally bemeasure outcomes in a valid and reliable way.[18]
avoided in elderly patients.[26] While this broadenedIn contrast, explicit screening criteria (e.g. look
the scope of the Beers criteria, it still did not result infor the inappropriate combination of cotrimoxazole
a complete set for medication reviewing.and a coumarin anticoagulant) have the advantages
of being reliably based on a literature review and
expert consensus opinion, they can identify and 3.2 Medication Appropriateness Index
prioritise problems in a consistent way and they can
A well known example of an implicit screeningbe easily incorporated into practice computer sys-
tool for reviewing medication patterns in elderlytems. However, explicit screening methods have the
patients is the Medication Appropriateness Indexdisadvantage of an inflexible approach, which
(MAI).[27-29] The first version of this index wasleaves insufficient room for individual differences
published in 1992 by Hanlon et al.[30] and a modifiedbetween patients and can thereby lead to false-posi-
version was presented by the same group in 1997.[31]tive signals (i.e. the signalling that a drug-related
The index raises a number of important issues thatproblem exists whereas in reality it does not exist).
are incompletely or not considered at all by theFurthermore, explicit screening methods will miss
Beers criteria. For example, has each medication anany drug-related problem that has not been pre-
indication? Is it expected to be effective for thespecified and will therefore fail to provide a full
patient’s condition? Is each dosage correct? Are theassessment of the patient.[18]
directions for use correct and practical? Are thereUsing a combination of implicit and explicit
any clinically significant drug-drug interactions orscreening methods can be expected to offer a more
drug-disease interactions? Is there any unnecessarythorough assessment than using either approach sep-
duplication with another drug? Is the duration ofarately. The only caveat with this strategy is that use
therapy acceptable? Is each medication the leastof such a combined application can be more time
expensive alternative compared with others of equalconsuming and care should therefore be taken to
utility? Contrary to the Beers criteria, the MAI doesensure the feasibility of this approach in daily prac-
not specify which drug therapies or drug combina-tice.[18]
tions are of primary concern in these domains. How-
ever, even the MAI does not cover all relevant3.1 Beers Criteria
categories of drug-related problems. For instance, it
A widely advocated explicit screening tool was does not address such important issues as adherence
introduced in 1991 by Beers et al.[19] The tool was to each medication regimen[7] or the risk that the
first developed to be used in nursing home patients patient is not receiving a required medication.[32,33]
© 2007 Adis Data Information BV. All rights reserved. Drugs Aging 2007; 24 (9)
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3.3 Assessing Care Of Vulnerable Elders rious other papers about general aspects to consider
(ACOVE) Indicators when reviewing medications,[3,15,18,26,31,32,36,38-44] we
identified a large number of issues that should be
The Assessing Care Of Vulnerable Elders taken into account in the implicit screening of medi-(ACOVE) indicators offer a mix of explicit and
cation patterns in outpatients.implicit screening criteria. In 2001, a series of con- Following the classification of medication re-
sensus-based sets of ACOVE indicators were pub-
views by the UK Task Force on Medicines Partner-lished as a special issue of the Annals of Internal
ship (table I), we divided these issues into prescrip-Medicine. A few years later, the results of applying tion, treatment and patient issues (table II). Sections
these indicators to assess the quality of medical care 5–7 discuss these categories individually, identify
and pharmacological care for vulnerable elderly pa- the general issues in each category and illustrate
tients were presented in the same journal.[34,35]
each general issue with specific examples and/orOne of the ACOVE sets of indicators focuses on detailed references to such examples.
appropriate medication use. This set consists of 12
different indicators, which range from very specific 5. Prescription Issues
topics (e.g. avoid barbiturates if they are not needed
Prescription issues often focus on cost reduction.to control seizures; check electrolytes within 1 week
While achieving cost effectiveness is a legitimateof initiating therapy with a thiazide or loop diuretic
objective of a medication review, it should alwaysand at least annually thereafter) to very broad rec-
be subordinate to improved care and safety.[15]ommendations (e.g. every new drug should have a
clearly defined indication; the patient or caregiver
5.1 Generic Substitutionshould be educated about every new drug in regard
to its purpose, how to take it and its expected ad- Consider the possibility that medications may be
verse effects; every vulnerable elderly patient substituted by cheaper generic equivalents
should undergo a drug regimen review at least annu- Generic substitution, which involves the substitu-
ally).[32] In addition, various drug therapy-related tion of a medication with a cheaper medication with
indicators are incorporated in the other ACOVE sets the same active ingredient(s), drug strength(s) and
of indicators.[36] For example, the set for the man- dosage form, can offer substantial economic bene-
agement of osteoarthritis recommends that paraceta- fits.[45,46] It can usually be performed safely if suffi-
mol (acetaminophen) should be the first drug used cient attention is paid to the following caveats:[47-49]
and that this drug should be administered at maxi-
• The risk of inequivalence is smaller when drug
mum dosage (taking into account age and co-mor- licensing authorities verify systematically and
bidity) before switching to another agent.[37] rigorously that generic products are bioequiva-
Although the ACOVE indicators highlight some lent to original brand products and to each other.
important aspects of drug therapy in the elderly that The risk of inequivalence is larger when this is
are not covered by either the Beers criteria or the not the case.[48]
MAI (e.g. the risk of under-prescribing and the need
• The risk of inequivalence depends on the specific
to monitor certain drug therapies carefully), neither dosage form and specific drug substance. Cau-
their range of general drug-related topics nor their tion is especially needed when the dosage form
selection of drug-specific indicators are exhaustive. has controlled-release properties[50-52] and when
the drug substance has a narrow therapeutic in-4. General Issues in Implicit Screening dex (e.g. antiepileptics, warfarin).[53,54]
Based on our earlier review of the quality man- • It is important to be alert to the occasional possi-
agement of repeat prescriptions,[2] two original stud- bility that an individual patient is confused by
ies of user- and prescriber-related problems in elder- differences in outward appearance (e.g. colour,
ly outpatients receiving polypharmacy,[16,17] and va- shape, packaging) or in the content of the pack-
© 2007 Adis Data Information BV. All rights reserved. Drugs Aging 2007; 24 (9)
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Table II.  General issues in the implicit screening of medication patterns in outpatients
Prescription issues
Consider the possibility that medications may be substituted by cheaper generic equivalents
Consider the possibility that medications may be substituted by cheaper therapeutic equivalents
Treatment issues
The reason for prescribing should be known to the medication reviewer
Consider discontinuation of medications without well established effectiveness
Consider discontinuation of medications without effectiveness and/or valid reason for use in the particular patient under review
Consider the possibility of potentially inappropriate duplication of drug treatment
Consider the possibility that one or more medications may have been added to an existing drug therapy to combat an adverse effect of
one or more medications already being taken
Consider elimination of medications that are potentially inappropriate for the patient under review (e.g. because of the patient’s age or
because an adverse effect has developed)
Consider whether the dosage of each medication is still appropriate
Consider whether medications are prescribed for an inappropriately long period
Consider whether medications have been prescribed for an inappropriately short period
Consider the risk of potentially inappropriate drug-disease interactions
Consider the risk of potentially inappropriate drug-drug interactions
Consider the risk of potentially inappropriate duplication of adverse effects
Consider the possibility that a required medication is inappropriately missing
Consider the appropriateness of drug treatment in the light of organ functions, such as renal and hepatic function
Consider the appropriateness of drug treatment in the light of electrolyte levels
Consider the appropriateness of drug treatment in the light of pharmacogenetic test results
Patient issues
Direct contact between reviewer and patient (or caregiver) offers essential advantages
Ask the patient what he/she knows about his/her medications and condition(s), which medications he/she actually takes and how he/
she takes them, which beneficial and unwanted effects he/she experiences and which queries the patient has himself/herself
Make adequate room for the patient perspective
Consider the possibility that the patient is taking less of the medication(s) than prescribed
Consider the possibility that the patient is taking more of the medication(s) than prescribed
Consider earlier patient experiences with drugs
Consider specific patient characteristics and habits
Consider the need for special packaging
Consider whether the patient is able to self-administer dosage forms that require special skills
age insert.[55] A particular concern is the risk associated with this approach often seem larger than
of confusion over original brands and parallel- what can be achieved by generic substitution.[56,57]
imported equivalents with different brand names. However, the pharmacotherapeutic caveats that
should be respected in order to guarantee therapeutic
equivalence are also of a different order. Drug sub-5.2 Therapeutic Substitution
stances with the same mechanism of action may still
Consider the possibility that medications may be be different with respect to ancillary pharmacologi-
substituted by cheaper therapeutic equivalents cal properties, safety profile and/or the risk of drug-
A step beyond generic substitution is class substi- drug interactions, which may lead to differences in
tution, in which medications are replaced by cheaper effectiveness, safety or applicability.[58-60] For in-
medications consisting of another substance from stance, there is substantial evidence to suggest that
the same drug class. This type of substitution is a β-adrenoceptor antagonists are not always equal
key component of many drug formularies and refer- with respect to their effectiveness[61-63] and that the
ence pricing systems, and the potential cost savings classical NSAIDs show notable differences in their
© 2007 Adis Data Information BV. All rights reserved. Drugs Aging 2007; 24 (9)
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adverse reaction profiles.[64,65] An additional con- • expectorants for acute bronchitis;[75,76]
cern is that studies evaluating clinical endpoints are
• long-term use of low-dose oral corticosteroids for
usually not available for all drug substances belong- stable chronic obstructive pulmonary disease
ing to the same cardiovascular drug class. Even if (COPD);[77]
one assumes that the effects on cardiovascular
• most phytotherapeutic agents for most indica-
endpoints are class effects, it may be difficult to tions[78,79] and homeopathic agents for any indi-
ascertain which dose levels are appropriate for those cation.[80,81]
substances that have not been evaluated in endpoint Consider discontinuation of medications without ef-
trials. This is especially a problem when monitoring fectiveness and/or valid reason for use in the partic-for a pharmacological effect (e.g. on cholesterol
ular patient under reviewlevel or blood pressure) is either impossible or inad-
Many medications may be stopped in elderly
equately executed.[60,66]
outpatients without the occurrence of an adverse
drug withdrawal event. However, such withdrawal6. Treatment Issues
events are known to occur, and if they do, they result
The reason for prescribing should be known to the in substantial healthcare utilisation. One should
medication reviewer therefore be vigilant for disease recurrence when
A general point with respect to treatment issues is drug therapy is discontinued in the elderly.[82,83] A
that medication reviewers may identify and evaluate list of drugs that qualify for careful consideration of
certain types of problems only, or at least more their discontinuation in the elderly has been drawn
easily, when they have access not only to the phar- up by Woodward.[41] Well known examples include:
macy record but also to the medical record. In a
• Loop diuretics. In a study evaluating use of loop
recent UK evaluation of pharmacist-led medication diuretics in Dutch community-dwelling patients
reviews in patients aged >65 years, pharmacists aged ≥75 years, GPs considered their continua-
detected 18% of drug-related problems by review- tion unnecessary for 19.5% of patients. The rea-
ing medical notes (in addition to 52% detected by son for use of these agents was unknown in 8% of
looking at prescription records and 29% by inter- patients, and they were used for the controversial
viewing patients at home).[67] Evidence that the indication of ankle oedema in another 8% of
quality of a pharmacist-conducted medication re- patients.[84]
view increases as access to complete patient infor-
• Histamine H2 receptor antagonists and proton
mation increases also arises from a US study of pump inhibitors. Studies in general populations
paper cases involving prescribing problems that had have shown that these acid suppressants are notbeen identified from patient charts.[68]
always used for a valid reason[85,86] and that an
appreciable proportion of long-term users is able6.1 Potentially Superfluous Medications
to discontinue these drugs.[87,88] A recent epide-
Consider discontinuation of medications without miological study suggested that use of proton
well established effectiveness pump inhibitors for >1 year is associated with an
Examples of medications with marginal or ques- increased risk of hip fracture in elderly users,
tionable effectiveness include: possibly as a result of interference with calcium
absorption.[89]• ergoloid mesylates and piracetam for dementia or
cognitive impairment;[69,70] • Cholinesterase inhibitors and memantine. As
• betahistine for Meniere’s disease;[71] these agents produce clinically relevant effects in
• most oral vasodilators for intermittent claudica- only a minority of patients with Alzheimer’s
tion;[72,73] disease,[90,91] it is important to assess after initia-
• antispasmodic or anticholinergic agents for irrita- tion of such therapy which patients respond and
ble bowel syndrome;[74] which patients do not.[92]
© 2007 Adis Data Information BV. All rights reserved. Drugs Aging 2007; 24 (9)
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• Anticholinergic medications for the treatment of This so-called ‘prescribing cascade’ may place the
overactive bladder.[41] The clinical benefits of use patient at risk of developing additional adverse ef-
of these agents to treat overactive bladder may be fects relating to this potentially unnecessary treat-
of questionable significance in many patients.[93] ment. Examples include addition of:[104,105]
• an antihypertensive to NSAID therapy (because• Antihypertensive medications in very old pa-
of an increase in blood pressure);tients. The benefits and risks of antihypertensives
• levodopa to metoclopramide treatment (becausein patients aged >80 years are still unclear.[94-96]
of parkinsonian symptoms);Preliminary results of a controlled trial of antihy-
• an acid-suppressant drug to a nitrate or calciumpertensive agents in this age group suggested that
channel antagonist (because the latter drugs maythe risk of stroke may be reduced but that this
precipitate gastroesophageal reflux by decreasinggain may be offset by extra non-stroke deaths.[97]
lower oesophageal sphincter pressure);[106]Trials of withdrawal or lowering of the dosage of
antihypertensive medications in elderly outpa- • a cough suppressant to treatment with an ACE
tients have shown that this approach may be inhibitor (because of a dry persistent cough);[107]
successful in up to 40% of patients when com- • a cholinesterase inhibitor to drug treatment capa-
bined with salt restriction and weight loss.[94] ble of impairing cognition;[108]
• an anticholinergic drug to medications that are• Oral mucolytics. A recent review suggested that
capable of inducing urinary incontinence,[109,110]treatment with these agents is not cost effective in
such as cholinesterase inhibitors for the treatmentall patients with chronic bronchitis or COPD and
of dementia.[111,112] The possibility that drug-in-that their use should be restricted to patients with
duced urinary incontinence may have triggeredmore frequent and severe exacerbations.[98]
the addition of an absorbent incontinence productConsider the possibility of potentially inappropriate
should also be considered;[113]duplication of drug treatment
• a drug for benign prostatic hyperplasia to anti-Unnecessary duplications of drug treatments
cholinergic medications (to combat urinary hesi-(different brands of the same drug or different drug
tation).[114]substances from the same therapeutic class) should
In such cases, it should be evaluated whether thebe avoided.[99,100] For instance, concurrent use of
causative drug can be withdrawn or substituted withmore than one NSAID may increase the risk of
another medication that does not have the samegastroduodenal toxicity.[101]
adverse effect.A particular risk of unnecessary duplication may
In the past, addition of an antigout agent to aoccur when drug substances or preparations with the
thiazide diuretic was also commonly listed as ansame pharmacological effects are applied for differ-
example, but a recent study has cast doubt on theent therapeutic reasons, for example, α-adrenocep-
validity of the underlying assumption that thiazidetor antagonist agents for hypertension and benign
diuretics actually increase the risk of gout.[115]prostatic hyperplasia, or norepinephrine/serotonin
reuptake inhibitors for depression and urinary in-
6.2 Potentially Inappropriate Medications
continence.[102] Patients are at particular risk of drug
duplication in the period immediately following dis- Consider elimination of medications that are poten-
charge from hospital.[103] tially inappropriate for the patient under review
Consider the possibility that one or more medica- (e.g. because of the patient’s age or because an
tions may have been added to an existing drug adverse effect has developed)
therapy to combat an adverse effect of one or more Since adverse drug effects can have profound
medications already being taken clinical and economic consequences for elderly pa-
A new medication may be added to an existing tients, Beers et al.[19,116] have identified a large num-
drug regimen to combat an adverse drug reaction. ber of drugs and drug classes that should generally
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be avoided in the elderly (see section 3.1). The Compared to the young, elderly patients show a
reader is referred to table I in the 2003 update of more marked variability in hepatic and renal func-
these so-called Beers criteria for the most recent tion, and this may be accentuated by differences in
version.[26] A few comments are in order. First, the intake of food, co-medications and pharmacogenetic
reasons for including nitrofurantoin (potential for influences. Furthermore, elderly patients may have
renal impairment and availability of safer alterna-
altered sensitivity to anticoagulants, cardiovascular
tives) are incorrect.[117] It is true only that nitrofuran- drugs and psychotropic drugs at the pharmacody-
toin should not be given to patients with renal im-
namic level.[133-136] As a result, individual elderlypairment, the reason being that antibacterial concen-
patients may need reduced dose levels and an initial-trations in the urine might not be attained whereas
ly correct dosage may therefore become less appro-the risk of toxicity (peripheral neuropathy, hepatic
priate.[25,137,138]reactions) is increased.[102,118,119] Secondly, the
Beers criteria should not be applied indiscriminate- The need to explore lower dosages is particularly
ly, because there may be acceptable reasons why relevant for medications with a narrow therapeutic
some of the listed medications are prescribed to index, such as lithium,[139] digoxin,[140] theophyl-
elderly patients (e.g. low-dose amitriptyline for neu- line,[141] metoclopramide,[142] tricyclic antidepres-
ropathic pain[120]). Thirdly, the Beers listing is not
sants,[143] antipsychotic agents,[144] sulphonylurea
without omissions, if only because it focuses on the
agents,[121] dopaminergic antiparkinson agents,
medications that are available in the US. Prominent
sedating antiepileptic agents, opioid analgesics andexamples of medications that are excluded but
verapamil.[145,146] Adjustment of drug dosages to anshould nevertheless be considered as potentially in-
appropriate geriatric level can also be relevant whenappropriate for the elderly are:
prescribing drugs without a narrow therapeutic in-
• glibenclamide (glyburide), because its long dura-
dex. It has been repeatedly observed, for instance,tion of action can result in prolonged and recur-
rent hypoglycaemia in elderly patients;[121-123] that use of high doses of benzodiazepines by elderly
• theophylline (unless its plasma levels can be individuals is associated with an increased risk of
closely monitored), because it has a narrow thera- hip fractures.[147,148]
peutic index and because its plasma level is sensi- When low-dose therapy is considered in elderly
tive to reduced clearance, underlying diseases patients, care should be taken to avoid the possibility
and drug-drug interactions;[124-126]
that concerns about adverse effects results in admin-
• quinine and hydroquinine, especially when used istration of an inappropriately low dosage.[133,149]for longer than a few weeks, because their mod-
This risk is illustrated by a North American studyest and variable effects on restless legs or noctur-
that evaluated patterns of prescription of warfarin innal muscle cramps are outweighed by the risk of
frail older people with atrial fibrillation and foundadverse reactions, such as cinchonism, thrombo-
that international normalised ratio levels were main-cytopenia and hemianopsia;[102,127-129]
tained below the established therapeutic range in• atypical antipsychotic agents in higher doses,
which entail a risk of serious adverse reactions in 45% of patients.[150]
the elderly and in certain conditions (e.g. Parkin- When prescribing and dispensing specific geriat-
son’s disease, dementia).[130-132]
ric dosages, it should be realised that elderly patients
may find it difficult to split tablets into two equal
6.3 Potentially Inappropriate Dosages halves, even when tablets are provided with a score
line. Tablets that already provide the lower dose
without the need for splitting are therefore prefera-Consider whether the dosage of each medication is
ble.[151,152]still appropriate
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6.4 Potentially Inappropriate Duration thirds of patients from general populations, but they
of Treatment are labour intensive, as they involve gradual taper-
ing of the dosage to minimise the risk of withdrawal
Consider whether medications are prescribed for an symptoms.[158,159] Minimal intervention strategies
inappropriately long period invite patients to stop on their own or to attend for an
Repeat prescribing without direct doctor-patient evaluation consultation (e.g. by a letter making them
contact entails the risk that there is no longer ade- aware of the risks involved). This type of interven-
quate control of whether every repeat prescription is tion is much less labour intensive and is successful
still appropriate, effective and well tolerated, and in about one-fifth or one-quarter of patients from
that it is still considered and taken by the patient as general populations.[158,160]
intended.[2] In a recent US study, excessive duration Consider whether medications are prescribed for an
of drug therapy was one of the five most common inappropriately short period
reasons for interventions by pharmacists, account- The prescription period for medications should
ing for almost 10% of all interventions.[153] A partic- not be too short either. For instance, patients with
ular problem with repeat prescribing is that GPs major depression should receive antidepressant
frequently continue drug therapies that have been treatment for at least 3–6 months after an initial
initiated by medical specialists. Although GPs often response to decrease the risk of relapse or recur-
indicate that this particular part of their prescribing rence.[161,162] However, it should be realised that a
behaviour cannot be changed, they have their own medication review is not an optimal method for
responsibility when repeating specialist-initiated ensuring adequate minimal treatment periods be-
prescriptions.[2] cause it can only identify cases retrospectively, and
Prolonged use of antibacterials can be justified therefore after use of the drug has already been
for certain indications (e.g. tuberculosis or long- discontinued (see also the topic of drug persistence
term prophylaxis of urinary tract infections) but may in section 7.2).
be unadvisable in other situations. For instance,
repeating antibacterial prescriptions for a lower re- 6.5 Drug-Disease Interactions
spiratory tract infection should be the exception
rather than the rule in general practice.[154] Likewise, Consider the risk of potentially inappropriate drug-
the suggested duration of treatment with an oral disease interactions
anticoagulant after venous thromboembolism varies For listings of drug-disease interactions that are
from 5 weeks to indefinitely, depending on the type potentially harmful to elderly patients, the reader is
of event and patient-related risk factors.[155] referred to McLeod et al.[163] and Fick et al.[26] The
The Beers criteria advise against the long-term occurrence of such drug-disease interactions in eld-
use of stimulant laxatives (e.g. bisacodyl, cascara erly patients in the US has been studied by Lindblad
sagrada), except in the presence of an opioid analge- et al.[164] and Zhan et al.[165] A particular concern in
sic, and against the long-term use of a full dosage of this domain is that strict adherence to current
a nonselective NSAID with a longer half-life (e.g. clinical practice guidelines may have undesirable
naproxen, oxaprozin, piroxicam).[26] effects when caring for elderly patients with several
Long-term anxiolytic or hypnotic use of benzodi- co-morbidities. Boyd et al.[166] constructed a hypo-
azepines and related substances is limited by serious thetical case of a 79-year-old woman with five
problems of dependence. Continuation of such use chronic diseases (osteoporosis, osteoarthritis, type 2
without any attempt at drug withdrawal or dose diabetes mellitus, hypertension and COPD) and dis-
reduction should generally be discouraged.[156,157] covered that concurrent adherence to all five clinical
Strategies for discontinuation can be divided into practice guidelines for these diseases in the US
gradual discontinuation programmes and minimal resulted in potential interactions between a medica-
interventions. The former may be successful in two- tion and a disease other than the target disease,
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between medications for different diseases and be- whether any contraindicated drug-disease combina-
tion that should already have been avoided beforetween food and medications. They also found that
the patient started the therapy has in fact not beenrecommendations could also contradict one another.
avoided.If the hypothetical osteoporotic, diabetic patient had
peripheral neuropathy, the osteoporosis clinical
6.6 Drug-Drug Interactionspractice guideline recommended that he/she per-
form weight-bearing exercise, whereas the diabetes
Consider the risk of potentially inappropriate drug-clinical practice guideline cautioned that some pa-
drug interactionstients with advanced peripheral neuropathy should
For general background information on drug-avoid weight-bearing exercise.
drug interactions, the reader is referred to textbooksWhen clinical information is not available, con- in this domain.[171-173] Medication reviewers should
currently used medications may serve as more or be aware that pharmacists have a tendency to assessless suitable surrogate markers for disease states, for the risk of a drug-drug interaction most thoroughly
example, insulin for diabetes,[167] nitrate prescrip- before the combination is dispensed for the first
tions for ischaemic heart disease[168] and digoxin or time.[174] However, there are also drug-drug interac-
amiodarone for atrial fibrillation.[40] tions that do not require strict avoidance but which
Medication reviewers should bear in mind that should be carefully monitored to prevent adverse
contraindications to use of a drug may arise long consequences (see table III for a selection).
after long-term therapy with that drug has been Medication reviewers should also check whether
established.[169] One reason is that the health status any drug-drug combination the patient is taking
of the patient can change over time, for example, should have been prevented before it was started.
because a new co-morbidity develops or because the Malone et al.[176] developed a list of 25 clinically
patient has grown much older than he/she was at the important drug-drug interactions that are likely to
start of treatment. For a US list of specific drug- occur in outpatients and that should be avoided as
disease combinations that should generally be much as possible. Application of this list to a large
avoided in the elderly, the reader is referred to table US prescription claims database revealed that 0.8%
II in the most recent version of the Beers criteria.[26] of patients had been exposed to a drug-drug interac-
A new contraindication may also develop when a tion on the list. The highest prevalence (278.56 per
drug is found to be less safe than it was initially 100 000 persons) and highest case-exposure rate
assumed to be. For instance, it has become clear that (242.7 per 1000 warfarin recipients) were found for
cyclo-oxygenase 2 inhibitors are associated with a warfarin plus an NSAID.[177] Other publications
degree of cardiovascular risk, which means they have also highlighted the need to check on contrain-
should not be used in patients with established is- dicated drug combinations[163,165,178-180] as well as
chaemic heart disease, cerebrovascular disease or the reasons why such combinations are not always
peripheral arterial disease, and that caution should prevented in daily practice.[181,182]
be exercised when prescribing these agents to pa- Consider the risk of potentially inappropriate dupli-
tients with risk factors for heart disease, such as cation of adverse effects
hypertension, hyperlipidaemia, diabetes and smok- Drugs from different drug classes may potentiate
ing.[170] each other, particularly in the elderly, when they
have similar adverse effects. Examples include:Medication reviewers should pay particular at-
tention to the assessment of relative contraindica- • Renal impairment. ACE inhibitors, NSAIDs and
tions, which do not strictly forbid use of a drug but diuretics can all impair renal function. The
which mandate careful follow-up of the patient to demonstrated advantages of these medications
avoid unnecessary adverse consequences. A medi- should therefore be carefully balanced against the
cation review also offers the opportunity to check risk of inducing renal failure by combining
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Table III.  Examples of drug-drug combinations that do not require strict avoidance but should be carefully monitored to prevent adverse
consequences (reproduced from De Gier,[175] with permission)
Drug-drug combination Potential risk Monitoring required
Digoxin + loop diuretics or thiazide diuretics Increased toxicity of digoxin Monitoring of potassium level
Sulphonylurea derivatives + chloramphenicol Increased effect of sulphonylurea derivative Monitoring of glucose level
Methotrexate + salicylates or NSAIDs Increased level of methotrexate and risk of Monitoring of renal function, hepatic
decreasing renal function function and blood parameters
Potassium-sparing diuretics + potassium Increased plasma level of potassium Monitoring of potassium level
supplements
Antihyperglycaemics + isoniazid Decreased glucose tolerance Monitoring of glucose levels
NSAIDs + ACE inhibitors or ARBs Decreased effect of ACE inhibitor or ARB; Dependent on indication for ACE
in patients with heart failure, addition of an inhibitor or ARB. If hypertension:
NSAID may lead to deterioration of renal monitoring of blood pressure; if heart
function and an increased potassium level failure: monitoring of symptoms (also by
patient)
β-Adrenoceptor antagonists + NSAIDs Decreased antihypertensive effects of β- Monitoring of blood pressure (if NSAID
adrenoceptor antagonist is used for longer period)
Loop diuretics + NSAIDs Decreased effect of loop diuretic In heart failure: monitoring of symptoms
(also by patient), renal function and
potassium level
ACE inhibitors or ARBs + potassium-sparing Increased plasma level of potassium Monitoring of potassium level
diuretics or potassium supplements
HMG-CoA reductase inhibitors (statins) + Risk of myopathy and rhabdomyolysis Combined use only under strict
ciclosporin, tacrolimus or fibric acid derivatives specialist monitoring
Corticosteroids + cytochrome P450 enzyme Decreased plasma level of corticosteroid Adjustment of corticosteroid dosage
inductors based on clinical picture
ARB = angiotensin II type 1 receptor antagonist (angiotensin receptor blocker).
them.[183-187] Similar caution also applies with falls in the elderly is the type Ia class of anti-
respect to combinations where angiotensin II arrhythmics,[203] and the risk that diuretics can
type 1 receptor antagonists are given instead of cause dizziness as a consequence of orthostatic
ACE inhibitors[187] and cyclo-oxygenase 2 inhibi- hypotension should also be taken into ac-
tors are given instead of classic NSAIDs.[188,189] count.[198]
• QT-interval prolongation.[190,191] • Confusion or delirium.[204,205]
• Anticholinergic effects.[111,192,193] Unexpected • Constipation.[114,206]
significant serum anticholinergic activity has al-
so been reported for drugs such as theophylline, 6.7 Under-Treatment
prednisolone and cimetidine.[194]
Consider the possibility that a required medication
• Dizziness, drowsiness and the risk of falls.[195-197]
is inappropriately missingRecent studies have suggested that certain drugs
Even when patients are already receivingincrease the risk of falls in a modifiable way that
polypharmacy, they do not always receive all theis independent of co-morbidity.[198,199] Centrally
drugs that are indicated for their condi-active drugs that have been associated with an in-
tion(s).[16,33,207-209] Examples of missing drugs in-creased risk of falls in the elderly include anxi-
clude:olytics, sedatives/hypnotics, antipsychotic
• Aspirin (acetylsalicylic acid). This should alwaysagents, antidepressants and antiepilep-
be considered in patients with angina pec-tics.[197,200,201] Short half-life benzodiazepines are
toris.[210,211]no safer in this respect than long half-life
benzodiazepines.[197,201,202] An important cardio- • Bisphosphonates. A bisphosphonate is often re-
vascular drug class that has been associated with quired by patients receiving high daily doses of
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corticosteroids to protect them against osteo- ticularly promising development in this field is im-
porosis.[212,213] proved linkage between the pharmacy and the labo-
ratory.[227] Pharmacy-initiated medication reviews• Laxative therapy. This is often needed to treat or
are certainly amongst the pharmaceutical servicesprevent opioid-induced constipation.[214]
that will benefit from increased availability of labo-• Gastroprotective agents. Elderly users of
ratory test results. Clinical pharmacists have muchNSAIDs may need gastroprotective agents if
experience, of course, with laboratory measure-their NSAID therapy cannot be stopped.[215-217]
ments of drug concentrations for therapeutic drug• Opioids. Elderly and demented patients with
monitoring and establishing adherence. However,chronic pain may need opioid agents.[218,219]
other types of laboratory data (e.g. blood lipid• Insulin therapy. This is not only a treatment op-
levels) can further improve the assessment of drugtion for younger patients with type 2 diabetes but
effectiveness and patient adherence. In addition,also for elderly patients with this disease.[220]
results from organ function tests, blood cell countsThere is increasing evidence that elderly popula-
and electrolyte and enzyme determinations willtions may benefit as much from certain cardiovascu-
greatly advance the evaluation of drug safety issueslar drug therapies as younger adults do, which in-
already discussed. For instance, concerns about thecreases the range of medications that may be miss-
safety of digoxin in an elderly patient can be sub-ing in elderly patients. Relevant examples include:
stantially mitigated by information about renal func-
• HMG-CoA reductase inhibitors (statins). Not on-
tion.[228]ly middle-aged patients but also patients aged
>70 years can benefit from statin treat- Consider the appropriateness of drug treatment in
ment.[221,222] the light of organ functions, such as renal and
• ACE inhibitors. Use of ACE inhibitors was asso- hepatic function
ciated with a significant survival benefit in a As medication reviews are often performed in
retrospective study of hospitalised older heart
elderly patients, it is important to appreciate that
failure patients with perceived contraindications physiological changes in drug metabolism and ex-(hypotension, renal insufficiency, hyper-
cretion occur with aging. Remarkably, metabolic
kalaemia, aortic stenosis).[223] differences between older and younger adults are
• Warfarin. Treatment with warfarin should not be not characterised by a similar shift in all elderly
withheld from elderly patients with atrial fibrilla- people but rather with a sharp increase in variations
tion who are at high risk of a stroke.[224,225] among individual patients.[134,229]
When patients have several unrelated diseases
A quantitative estimate of renal function can beconcurrently, a particular concern is that one of
readily obtained by calculating creatinine clearancethese problems may consume attention at the ex-
on the basis of serum creatinine, age, gender andpense of the other problems. For instance, a Canadi-
weight of the patient. This calculated clearance canan study suggested that patients with diabetes are
then be used to adjust the dosage or administrationless likely to receive estrogen replacement therapy,
interval of various renally cleared medica-whereas patients with emphysema are less likely to
tions.[230,231] It is important to be aware that olderreceive lipid-lowering medications.[226]
patients may have impaired renal function despite
normal serum creatinine levels and are therefore6.8 Use of Laboratory Test Results
exposed to an increased risk of adverse reactions to
Increasing technological possibilities are making hydrosoluble drugs.[232] There is evidence to suggest
it more and more feasible for healthcare providers to that, even when renal function data are available,
access not only their own data file about a patient they are not systematically applied to establish the
but also data about that specific patient that have most appropriate dosage regimen.[227,233,234] Gui-
been filed by other healthcare professionals. A par- dance for this type of adjustment can be found in
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package inserts and pharmacotherapeutic textbooks, Pharmacogenetic test data are likely to become
more and more important for assessing and predict-but an important caveat is that such sources may not
ing drug efficacy and toxicity. This field began withyet be sufficiently evidence based.[235,236]
a focus on polymorphisms of drug metabo-Liver disease can also modify the kinetics of
lism,[255,256] and it is precisely in this domain thatmany drugs to an extent that dosage adjustment is
practical possibilities for improving the dosing ofrequired. While an analogous method for the simple
certain drugs (phenytoin, antidepressants, mer-and reliable quantification of hepatic clearance in
captopurine and azathioprine) are emerging or havedaily practice is not available, high bilirubin levels
already emerged.[257-261] However, pharmacogenet-or low albumin levels can provide qualitative evi-
ics is rapidly expanding to encompass a wide spec-dence that a dose reduction for hepatically cleared
trum of genetic variations in pharmacokinetic andmedications is necessary.[227,237,238]
pharmacodynamic patient profiles.[262-264] While the
As the kidney and liver are important sites of practical application of this knowledge still largely
drug toxicity,[189,239,240] renal and hepatic function lies in the future,[265,266] the moment when such data
data can also be applied to prevent the injudicious become applicable within the framework of a medi-
continuation of a nephrotoxic or hepatotoxic medi- cation review is coming nearer. It is therefore impor-
cation in patients with renal or hepatic impairment. tant to design new systems for improving the availa-
Besides renal and hepatic impairment, there are bility of laboratory data to medication reviewers in
also other organ dysfunctions that can be recognised such a way that pharmacogenetic test results can be
on the basis of laboratory test results and that can taken into account.
affect drug efficacy and drug safety.[241,242] For in- When this occurs, pharmacogenetic parameters
stance, it has been recognised for many years that will only rarely be a review issue in themselves (e.g.
thyroid disorders affect the pharmacokinetics of a factor V Leiden mutation as a contraindication for
propranolol and can alter sensitivity to digoxin, anti- use of oral hormonal contraceptives[267]). More oft-
coagulants and sedatives.[243,244] en, they will act as a risk modifier in relation to an
already existent review issue, contributing to deci-Consider the appropriateness of drug treatment in
sions about the appropriateness of:the light of electrolyte levels
• Drug choice. For example, there is increasingCertain drug-related risks are substantially mag-
evidence that response to selective serotoninnified by electrolyte abnormalities. For instance,
reuptake inhibitors is partially dependent on sero-hypokalaemia predisposes to adverse reactions to
tonin transporter promoter polymorphism[268] anddigoxin[102] and to the induction of torsade de
that antidepressant response may also vary withpointes by drugs such as sotalol and psychotropic
other pharmacodynamic polymorphisms.[269]agents.[245,246] Conversely, many drugs are capable
While it would be quite premature to determineof inducing abnormal levels of sodium, potassium,
such parameters in daily practice for the purposecalcium, magnesium or phosphorus.[247-250] In recent
of predicting clinical response, this might oneyears, there have been particular concerns about
day become a feasible reality.drug-induced hyponatraemia[250,251] and hyper-
kalaemia.[252,253] It has been demonstrated, for in- • Dose regimens. Improving dosages of phenytoin,
stance, that addition of spironolactone to an ACE antidepressants, mercaptopurine and azathi-
inhibitor in the treatment of heart failure entails a oprine are examples that have been discussed
serious risk of life-threatening hyperkalaemia if po- earlier in this section.
tassium levels and renal function are not closely
• Drug-drug combinations. For example, allelic
monitored.[254] variants of cytochrome P450 enzyme (CYP) 2C9
Consider the appropriateness of drug treatment in magnify the risk of an interaction between oral
the light of pharmacogenetic test results anticoagulants and NSAIDs.[270]
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• Drug-herb combinations. For example, hyper- graph, the last issue is certainly not the least impor-
icum (St John’s wort) produces a significant in- tant one.
crease in CYP2C19 activity in extensive Make adequate room for the patient perspective
CYP2C19 metabolisers but not in poor Medication reviewers assessing the appropriate-
metabolisers.[271]
ness of drug therapy should not restrict themselves
to medical and pharmacological points of view, but7. Patient Issues
rather should also incorporate the patient’s perspec-
Direct contact between reviewer and patient (or tive on medication appropriateness in their evalua-
caregiver) offers essential advantages tion.[275,276] For instance, a physician prescribing
drugs for an elderly patient may be primarily occu-For a proper assessment of user-related issues, it
pied with treating medically diagnosed diseases,is essential to combine the review of prescription
whereas the patient might be more interested inrecords and/or medical records with an interview of
treatment that will reduce functional decline andthe patient or caregiver to elucidate such aspects as
disabilities.[277,278]actual medication-taking behaviour and experiences
of adverse effects.[2] In a UK intervention including Qualitative research of the patient perspective on
a patient interview, such direct contact was consid- medication reviews indicates that patients and carers
ered most influential; potential changes were dis- want to tell the reviewer about their personal beliefs,
cussed with the patient to determine whether the preferences and concerns, and they want to verify if
patient would be intolerant of change. Agreeing on they are taking the best medicines for their
suggested changes with the patient made implemen- problems.[279] To ensure their needs are recognised,
tation less time consuming for the GP.[272] In a patients want: time specifically set aside for the
US study, 73% of the problems identified were interview; someone to listen carefully to their ques-
recognised only through a patient interview.[273] tions; clear explanations in simple language; an
In another US study, the longer the contact between open interaction in which they can be honest about
the reviewing pharmacist and patient, the more what they are actually taking; and honesty from the
problems were identified and resolved; personal reviewer about the consequences of taking (or not
contact identified and resolved more problems than taking) their medications.[279] Research has also
contacts by telephone.[274] shown that patients can get the most out of their
medication review if they know in advance why
7.1 Basic Issues they are coming, what to expect and how to pre-
pare.[280] It is therefore advisable to provide patientsAsk the patient what he/she knows about his/her
who are invited for a medication review (or who aremedications and condition(s), which medications
eligible for such a review) with educational materi-he/she actually takes and how he/she takes them,
als relating to these aspects.which beneficial and unwanted effects he/she exper-
iences and which queries the patient has himself/ Ideally, there should be a good rapport between
herself the patient and the professional reviewer at the pa-
Important issues to be raised during the patient tient interview. The reviewer should not consider
consultation are as follows. Does the patient know the interview an opportunity to reinforce instruc-
what the medications are for? Does he/she remem- tions around treatment (compliance), but rather as a
ber the dosage of each medication? Is he/she still situation in which the expertise of the patient and the
taking each medication as prescribed? Is he/she tak- professional are pooled to arrive at mutually agreed
ing any other medications (including any comple- goals (concordance).[281,282] It cannot be expected
mentary medicines)? Does he/she notice any bene- that every patient interview will result in a concor-
fits or adverse effects? Does the patient have any dant discussion of this type; this will depend on the
queries him/herself?[38] As outlined in the next para- approach and skills of the individual reviewer. How-
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ever, it is important that each interview be conclud- (e.g. peers, books, the Internet) than in their GP’s
ed with a summary of agreement between the patient advice. They may find it confusing when objective
and the reviewer about treatment and an explanation indicators show improvement but they do not feel
of what will happen next.[15] any better, or perhaps even feel worse. They may
also find it difficult to assess the long-term impact of
7.2 Non-Adherence preventive medications, which makes some patients
uncertain about whether the medication is truly nec-
Consider the possibility that the patient is taking
essary (e.g. antihypertensives). Some people haveless of the medication(s) than prescribed difficulty distinguishing the undesirable effects of a
Non-adherence to prescribed drug regimens is a
medication from the symptoms of their disease.
common and important problem. Depending on def- There are also worries about medications thatinition, detection method and user characteristics, layperson testing and evaluation cannot resolve,
non-adherence has been reported to range from 14%
such as fears about dependence, tolerance and ad-to 70%.[283-285] Self-determined drug discontinuation
diction, about masking more serious symptoms or(which could be conceived as the most drastic form
about the potential harm from taking medications onof non-adherence) may occur in up to 40% of occa-
a long-term basis. Another reason why people maysions.[286] Recent studies indicate that this non-per-
not take their medications as prescribed is that theysistence is a major problem for a range of drug
do not accept their illness and/or regard medicationsclasses intended for long-term use.[287-291] Factors
as an unwelcome reminder of that illness. Suchthat have been associated with non-adherence in-
people are unlikely to accept their drug treatment asclude the number of medications, the type of drug
prescribed. For instance, some people with asthmabeing taken, receipt of prescriptions from more than
downplay its significance, claiming either that theyone doctor, independence when taking medicines,
impaired cognitive function, probability of demen- do not have true asthma or only a slight form of the
tia, depression, cost of medications, insurance cov- condition. Such patients may leave out their preven-
erage and physician-patient communica- tive medications and take only reliever medications,
tion.[284,285,292-294] particularly in social or public situations. For certain
Non-adherence can be either unintentional (the drug classes (HIV agents, psychotropic drugs) and
patient cannot manage his or her medications) or in certain age groups (children), people may fear
intentional (the patient does not want to manage that disclosing their drug use to others will mark
them as prescribed). In the latter case, the beliefs of them out as being different from their peers, which
the patient (or caregiver) about illness and drug will lead to stigmatisation or discrimination.[297]
treatment play a crucial role.[295,296] A recent synthe- As a result of these considerations and concerns,
sis of qualitative research into the main reasons why
many people alter the way in which they take theirpeople do not take their medications as prescribed
medications, and they may do so without discussingidentified a number of important layperson themes
this with their doctors. They may decide not toaround medication taking.[297] According to this
initiate drug treatment, or to stop taking their medi-analysis, people evaluate their medications in their
cations altogether. They may also start to self-exper-own way and encounter difficulties when weighing
iment with their prescribed regimens by taking theirup the benefits of taking their medications against
medications symptomatically or strategically, or bythe disadvantages of doing so. They place hope in
adjusting dosages to minimise unwanted conse-their medications, but a key concern is worries about
quences or make a regimen more acceptable. Manyadverse effects. Another concern is whether a pre-
of these modifications reflect a desire to take as littlescribed regimen fits in with the patient’s daily life.
medication as possible, and sometimes this is alsoPeople may place more faith in their own observa-
evident from decisions to supplement or replacetions and/or in alternative sources of information
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drug therapies with alternative or non-pharmacolog- as possible to the type of non-adherence that is
ical treatments.[297] expected or observed: unintentional or intentional.
In the latter case, the most important prerequisite isAn obvious method of assessing adherence to
that discussions are based on a good rapport be-drug therapy in daily practice is to look for specific
tween the patient and the interviewer (see earlier inclinical effects (e.g. on cholesterol levels or blood
this section). In cases of unintentional non-adher-pressure). However, this is by no means a feasible
ence, the following possibilities should also be con-option for all drug therapies and measurements per-
sidered, depending on the specific problem(s) theformed during scheduled patient’s visits do not nec-
individual patient has.essarily provide an accurate picture of drug intake
• Educating patients who are not yet sufficientlybetween visits. Alternatively, it is possible to ask
aware of the necessity to adhere to their pre-questions of the patient, evaluate prescription refill
scribed medication regimens.patterns and/or perform pill counts. All of these
methods may help detect non-adherence to a certain
• Educating patients about practical ways to im-
degree, but they are all prone to a risk of overesti- prove adherence. For instance, helping patients
mating adherence, and their effectiveness varies select cues that will assist them to remember to
with the way in which they are implemented (e.g. take doses (time of day, meal-time or other daily
whether or not questions are asked in an open- rituals) can be beneficial. If this is ineffective, the
ended, non-judgemental way).[298-301] possibility of providing a compliance aid (such as
an auditory or visual alarm) may be contemplat-A more objective method is direct monitoring of
ed.[309]the effects of the treatment (e.g. by measuring blood
pressure, cholesterol levels or peak expiratory flow),
• Simplifying prescribed dosage regimens, for ex-
but this is not a viable option for all types of long- ample, once or twice daily instead of three to four
term medications. Another possibility is electronic times daily[310] and using fixed-dose combination
monitoring of drug intake by providing the medica- products instead of separate products for each
tion in a pill bottle with an electronic cap that drug substance.[311-313]
registers the time of each bottle opening. This ap-
• Weekly dispensing of medications in a multi-proach can not only detect different patterns of non-
compartment medication box or other time-spe-
adherence, but the mere fact that the patient knows
cific packing.[314,315] Although concrete evidence
that he/she is being monitored can stimulate him/her that this actually increases correct use is still
to become more adherent.[302,303] However, this elec-
meagre,[309,316,317] the approach has considerable
tronic method is not foolproof, as patients may take face validity.
out more than one dose at a time or open the bottle
If useful, these options can also be combinedwithout taking the medication.[304] Furthermore, ex-
with each other. In a recent randomised controlledperience with such monitoring electronic devices
trial in the US, a pharmaceutical care programmeoutside the strict setting of research studies is still
consisting of standardised medication education,rather limited.[305]
regular follow-up by pharmacists and dispensing ofGeneral reviews of interventions to improve
medications in time-specific packs increased medi-
medication adherence in patients with chronic dis-
cation adherence, medication persistence and clini-
ease have concluded that currently investigated
cally meaningful reductions in blood pressure.[318]
methods are mostly complex, labour intensive and
Consider the possibility that the patient is takingnot predictably effective, and that further studies of
more of the medication(s) than prescribedinnovative approaches are still needed.[306-308] Pend-
ing the results of more and better studies, it is Besides the risk of underuse, the possibility of
important in daily practice to tailor actions for the overuse must be considered for certain drug classes,
prevention and reduction of non-adherence as much such as inhaled β-adrenoceptor agonists,[319] benzo-
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diazepines,[320] opioid cough suppressants,[321] laxa- drug products[329] or strict adherence to the Ramadan
tives[322] and triptan derivatives.[323] rule of abstaining from any food, beverage or oral
drug from dawn to sunset.[330,331]
7.3 Patient Experiences and Habits A patient characteristic that particularly deserves
more attention than it has received to date is nutri-
Consider earlier patient experiences with drugs tional status, since nutritional deficiencies entail a
The patient’s earlier experiences with a particular risk of serious food-drug interactions. Frail elderly
drug or drug class can be relevant to the reviewer’s people are especially at risk because they may be
evaluation of the appropriateness of that patient’s subject to several risk factors, such as malnutrition,
use of medications. When a particular drug has been anorexia, alcoholism, chronic disease and polyphar-
ineffective or toxic in the past, it is important to macy.[133] On the one hand, impairment of nutrition-
prevent injudicious re-exposure to that particular al status and its consequent physiological alterations
drug or a closely related agent. For example, a can have a major impact on the pharmacology of
previous episode of NSAID-associated gastrointes- many drugs in the frail elderly. On the other hand,
tinal bleeding or ulcer is a relevant determinant of drugs often have, directly and indirectly, a deleteri-
future NSAID-associated gastrointestinal toxici- ous effect on the nutritional status of the elderly
ty.[216,217,324] In other words, when a patient has had individual.[332] A list of medications that can be
an NSAID-related gastrointestinal complication, it associated with undesired weight loss in older adults
is not acceptable to restart this NSAID under the has been compiled by Golden et al.[333]
same circumstances.[324,325] Likewise, benzodi-
azepines should not be restarted in ambulant elderly 7.4 Dosage Forms and Packaging
patients with a history of benzodiazepine-associated
Consider the need for special packagingfalls.[40,156]
It should be recognised that some patients mayA recent Dutch study identified elderly drug
have difficulty opening foil- or plastic-wrappedusers in whom drug regimens had been stopped
dose units because they have, for example, a rheu-during their hospital stay at a geriatric ward because
matic disorder.[334,335] When a patient seems to beof adverse reactions.[326] These patients were subse-
unable to cope with the complexity of his or herquently followed after their discharge to see whether
drug-taking regimen, weekly dispensing in a multi-the stopped drug regimens would be reintroduced
compartment medication box may be contemplatedoutside the hospital. The re-prescription rate was
(see section 7.2).27% within the first 6 months after discharge. Re-
prescription rates were not markedly different for Consider whether the patient is able to self-adminis-
patients with serious versus non-serious adverse ter dosage forms that require special skills
drug reactions or for adverse drug reactions men- Many patients have difficulties splitting tablets
tioned versus not mentioned in the discharge let- into two equal halves, even if the tablets are provid-
ter.[326] Clearly, there is a need for standardised ed with a score line.[151,152]
recording of patient experiences and easier ex- Patients may also lack adequate skills to self-
change of this information so that it can be systemi- administer certain dosage forms accurately because
cally taken into account in computerised medication of age- or disease-related deficits in cognitive skills,
surveillance systems and medication reviews. memory or physical dexterity. A good example is
Consider specific patient characteristics and habits the difficulties that elderly patients may have in
It can also be relevant to document diverse pa- using their inhaler device correctly.[336] As their
tient characteristics that may affect drug effects or perception of their own inhaler skills may not corre-
drug intake, for example, tobacco smoking,[327] a late with actual performance, it is important to ask
predilection for natural remedies,[78,328] religious be- older patients to demonstrate the appropriateness of
liefs that stand in the way of using porcine-derived their inhaler technique.[337] In one study of elderly
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individuals, failure to shake the device, poor coordi- reviewers, but also to spark further research into the
nation of actuation and inhalation and absence of clinical, humanistic and economic aspects of current
breath holding were the most common errors.[338] In drug utilisation patterns. We took account of recent
another study, major errors were more common with technological developments, such as better linkage
breath-actuated devices.[337] Unrecognised cognitive between the pharmacy and the laboratory and the
impairment or dyspraxia may render elderly patients increasing range of pharmacogenetic testing pos-
unable to learn to use an inhaler, and patients with sibilities. However, we also argued that medication
dementia are almost invariably unable to use any reviewers should not restrict themselves to a clinical
form of inhaler.[339] Another concern is that many perspective, but should also ‘stand next to’ the pa-
patients with asthma or COPD are treated with two tient so that his/her perspective of drug-related
or three different types of inhalation devices, which problems is also adequately taken into account. Ulti-
may compromise their competence to use each de- mately, it is the patient who must cope with his or
vice correctly.[340] her drug therapy, and it is the patient who makes the
decision to take medications as directed or not.Patients may also experience difficulties with the
One final point that must be raised is the need forapplication of eye drops, even to the point that self-
more studies of medication reviews evaluating rele-administered drops may not fall into the conjuncti-
vant outcomes. Studies that actually documentval sac. There are appliances that can help to im-
clinical and humanistic improvements after a medi-prove instillation, but care should be taken to select
cation review remain scarce.[1,2,349-352] Some studiesa device that targets the problem area of the individ-
have shown favourable trends[9] or significantly pos-ual user (e.g. alignment or squeezability).[341-343] In
itive results;[5,353] however, other studies have foundaddition, it is important to check whether patients
no influence on quality of life or re-hospitalisa-with a chronic condition continue to use the appli-
tion,[2,10,354] and in one study a negative effect on theance when their eye drop bottle is replaced by a
rate of hospital admissions was reported.[10] Furthernewly dispensed bottle.[344]
well designed studies are needed to explain suchAnother potentially worrisome dosage form is
counterintuitive findings. These studies should alsothe insulin injection.[315] Many elderly patients with
identify which specific methods of medication re-diabetes cannot self-administer insulin because of
view are the most effective and cost effective.poor dexterity, vision or cognitive skills.[345] In addi-
tion, users of neutral protamine Hagedorn insulin
Acknowledgementsmay not be able to mix this suspension adequate-
ly.[346,347]
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